Interferon B-1a for Clinically Isolated Syndromes Interferon B-1a for Clinically Isolated Syndromes

This study demonstrates that early initiation of treatment with subcutaneous interferon B-1a following a first clinical demyelinating event significantly delays conversion to multiple sclerosis.Journal of Neurology, Neurosurgery, and Psychiatry
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Neurology & Neurosurgery Journal Article Source Type: news